臨床使用Degarelix之血清前列腺特異抗原抑制效果及不良反應
盧顥文、黃立華、歐宴泉、許兆畬、童敏哲
童綜合醫院外科部泌尿外科
Serum prostate specific antigen suppression and adverse events of degarelix in clinical experience
Hao-Wen LU, Li-Hua Huang, Yen-Chuan Ou, Chao-Yu Hsu, Min-Che Tung,
Divisions of Urology, Department of Surgery, Tungs’Taichung MetroHarbor Hospital,
Taichung, Taiwan
Purpose: The most frequent use medication for androgen deprivation therapy in prostate cancer is luteinizing hormone releasing hormone(LHRH) agonist such as Leuprolide. However LHRH agonist can cause initial surge of testosterone with exacerbation of clinical symptoms. Degarelix is a new generation luteinizing hormone-releasing hormone antagonist which can avoid testosterone surge with potential advantage. We evaluate the efficacy of Dagarelix in serum prostate specific antigen(PSA) suppression and dealing with common adverse events in clinical practice.
Materials and Methods: From August 2017 to September 2017, a total 18 patients with advanced prostate cancer or biochemical failure after radical prostatectomy were enrolled. We analyzed the serum PSA value at the first visiting and after first dose of Degarelix (240mg) on Day28. Treatment related adverse events were recorded.
Results: The median serum PSA level is 53.32ng/mL on Day 1 and 11.01ng/mL on Day28, The median percentage change PSA level from baseline is 39.08%. The most common adverse event after Degarelix injection is pain of injection site (17/18, 94.4%) followed by hyperhydrosis(4/18) The median pain scale is 3.7 points in verbal descriptor scale, and median duration of injection site paiin is 4.5 days. Most adverse events are grade 1 which treatment were no needed.
Conclusions: Degarelix showed good safty and effective to most of our patients. We found Ice packing immediately after injection and the next 3days can reduce injection site pain.